Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenapanor in ESRD-HD Patients With Hyperphosphatemia
CTR20202588Phase 3Completed
- Sponsor
- Fosun Pharma
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenapanor in hyperphosphatemia, end-stage kidney disease (ESKD), sponsored by Fosun Pharma. Started Dec 2020; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on CTR20202588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202588.